UPCC 18223: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed o
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a phase 1 first in human, dose escalation trial in subjects with advanced pancreatic cancer previously treated with 5-Fluorouacil-based Chemotherapy but never exposed to therapeutic gemcitabine.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854402
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
